ReviewThe pharmacogenomics journal2026
Potential of pharmacogenetics in treatment of chronic inflammatory diseases - a danish report overview from 2000 - 2024.
Review in The pharmacogenomics journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Given the substantial degree of inter-individual variability in treatment responses in patients with inflammatory bowel disease (IBD), treatment optimization is warranted. We provide an overview of pharmacogenetic variants that can affect the efficacy or toxicity of drugs commonly used for IBD. We used The Danish Register of Medical Product Statistics for information about medical treatment from 2000 - 2024. Of the most used drugs Azathioprine, Mesalazine, and Sulfasalazine have pharmacogenetic recommendation guidelines and/or FDA annotations. Approximately 19,241 Danish individuals treated with azathioprine-around 801 annually-may carry a genetic variant for which pharmacogenetic dosing guidelines exist. Up to 13,934 Danish individuals using infliximab or adalimumab (~580 individuals each year) have a potential risk of developing immunogenicity related to monoclonal antibodies. This study shows the possibilities of pharmacogenetic testing as a supportive clinical decision tool to optimize treatment and minimize risk of e.g., serious adverse effects, remission, and other serious complications.
Indexed as
Identifiers
41735256What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.